Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06493526

PHASE4

Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch

Sponsor: University Hospital, Antwerp

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if calcineurin-inhibitor therapy (a drug commonly used to prevent rejection) can be safely stopped in kidney transplant recipients with a relatively low risk of rejection (being recipients of a first transplant, without any signs of pre-existing immunity against the graft, and having a good HLA match with the donor (no mismatch in HLA-DQ)). Before stopping the calcineurin-inhibitors, the remaining therapy with mycophenolate mofetil and corticosteroids will be optimized.The main questions it aims to answer are: Is this approach safe, in terms of preventing rejection? Is this approach well tolerated? Will this approach lead to better kidney function and/or other beneficial effects?

Official title: Safety of Calcineurin-Inhibitor Withdrawal in Zero-HLA DQ-Mismatched Kidney Transplant Recipients on a Concentration Controlled Mycophenolate Dose: A Prospective, Single Arm Pilot Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-08-20

Completion Date

2027-06-30

Last Updated

2024-08-21

Healthy Volunteers

Conditions

Kidney Transplantation

Interventions

DRUG

Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.

Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.

Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Adults ≥ 18 years old who received a first, zero-HLA-DQ mismatched kidney transplant between 3 and 12 months before screening. ((mis)matching based on the broad Eurotransplant Match determinant for DQA1 and on the split Eurotransplant Match determinant for DQB1 * Maintenance immunosuppressive therapy should consist of a calcineurin-inhibitor (tacrolimus or cyclosporine), MMF and corticosteroids * subjects capable of giving informed consent * eGFR ≥ 20 ml/min/1.73m² based on CKD-EPI Creatinine-Cystatin Equation at screening * Recent HLA antibody testing (\<6 weeks before screening) * Absence of DSA (MFI \> 500) at screening and in all historical samples * Absence of subclinical rejection on a protocol kidney transplant biopsy according to latest Banff criteria (excl. borderline lesions) * Recent assessment of CNI and MPA AUC (performed at least 8 weeks after transplantation, but \<12 weeks before screening, ) * Recent OGTT in patients not on antidiabetic therapy (\<3 months ago) Exclusion Criteria: * Receipt of a non-renal transplant * HLA identical sibling donor transplant * ABO incompatible kidney transplantation * cdc-PRA at transplantation \> 50% * Ongoing treatment with immunosuppressive drugs other than CNI, MMF/MPA and cortico-steroids * Prophylactic therapy with valganciclovir * History of biopsy-proven acute rejection * Unexplained rise in creatininemia \>20% over the last 6 weeks * Albuminuria \> 1g/day ( based on latest 24h urine collection max 6 weeks ago) * Chronic diarrhea or gastrointestinal disorders that interfere with the absorption or oral medi-cation * Active peptic ulcer disease * Active hepatitis B, hepatitis C or human immunodeficiency virus infection at the day of trans-plantation * New diagnosis of malignancy since transplantation, except successfully treated nonmetastatic basal or squamous cell carcinoma of the skin * Pregnancy or lactation * Patients unwilling to use reliable anticonception during the study (Male patients or their untreated female partner must use reliable contraception during my-cophenolate treatment and for at least 90 days after stopping MMF treatment. Female patients who can get pregnant must use at least one reliable form of contraception before, during and for 6 weeks after stopping MMF treatment)

Locations (1)

University Hospital Antwerp

Edegem, Antwerp, Belgium